Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

NCT03598244 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
41
Enrollment
NIH
Sponsor class

Conditions

Interventions

Sponsor

National Cancer Institute (NCI)